Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during...
NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of...
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Implemented cost reductions extend cash runway into first half of 2027BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant...
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a...
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may...
American Lung Association releases report detailing health benefits of transition to zero-emission manufacturing CHICAGO, Aug. 14, 2025 /PRNewswire/ -- Industrial...
NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical...
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire...
IRVING, Texas, Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision...
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce....
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation...
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation...
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences...
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences...
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...